Gelber, R. D.
, Wang, X. V., Cole, B. F., Cameron, D., Cardoso, F.
, Tjan-Heijnen, V., Krop, I., Loi, S., Salgado, R., Kiermaier, A., Frank, E., Fumagalli, D., Caballero, C., de Azambuja, E., Procter, M., Clark, E., Restuccia, E., Heeson, S., Bines, J., ... APHINITY Steering Committee and Investigators (2022).
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
European Journal of Cancer,
166, 219-228.
https://doi.org/10.1016/j.ejca.2022.01.031